Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
1998
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC03
|
| gptkbp:biosimilar |
yes
|
| gptkbp:brand |
gptkb:Herceptin
|
| gptkbp:CASNumber |
180288-69-1
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:discoveredBy |
gptkb:Dennis_Slamon
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab (antibody)
|
| gptkbp:indication |
metastatic breast cancer
early-stage breast cancer HER2-positive cancers |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HER2-mediated signaling
|
| gptkbp:molecularWeight |
148 kDa
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cardiotoxicity
infusion reactions |
| gptkbp:target |
gptkb:HER2_receptor
|
| gptkbp:type |
humanized antibody
|
| gptkbp:UNII |
P188ANX8CK
|
| gptkbp:usedFor |
gptkb:cancer
gastric cancer |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Trastuzumab_deruxtecan
|
| gptkbp:bfsLayer |
7
|